ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

TCDA Tricida Inc

0.108
0.00 (0.00%)
30 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Tricida Inc NASDAQ:TCDA NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.108 0.104 0.105 0 01:00:00

Tricida to Report Second Quarter Financial Results and Host Conference Call and Webcast on Monday, August 9, 2021

28/07/2021 6:00pm

GlobeNewswire Inc.


Tricida (NASDAQ:TCDA)
Historical Stock Chart


From May 2021 to May 2024

Click Here for more Tricida Charts.

Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its second quarter 2021 financial results after the close of market on Monday, August 9, 2021. Tricida will host a conference call and webcast at 4:30 pm Eastern Time to discuss its second quarter financial results and business progress. The webcast or call may be accessed as follows:

Tricida Conference Call Information

Tricida will host its Second Quarter Financial Results and Business Update Conference Call and webcast on Monday August 9, 2021 at 4:30 pm Eastern Time. The webcast and slide presentation or conference call may be accessed as follows:

 Tricida Conference Call 
 Monday, August 9, 2021 
 4:30 pm Eastern Time 
Webcast: IR.Tricida.com
Dial-In: (877) 377-5478
International: (629) 228-0740
Conference ID: 9679330

A replay of the webcast will be available on Tricida’s website approximately two hours following the completion of the call and will be available for up to 90 days following the presentation.

About Tricida

Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (also known as TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis and slow CKD progression in patients with CKD. Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. There are no FDA-approved treatments for chronic metabolic acidosis. It is estimated to pose a health risk to approximately three million patients with CKD in the United States.

For more information about Tricida, please visit www.Tricida.com.

Contact: Jackie CossmonTricida, Inc.Senior Vice President of Investor Relations and CommunicationsIR@Tricida.com

Source: Tricida, Inc.

1 Year Tricida Chart

1 Year Tricida Chart

1 Month Tricida Chart

1 Month Tricida Chart

Your Recent History

Delayed Upgrade Clock